HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $115
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $125 to $115.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $125 to $115.